About Ophirex
Ophirex is a company based in Corte Madera (United States) founded in 2015 by Matthew Lewin. Ophirex has raised $16.48 million across 2 funding rounds from investors including HHS. Ophirex offers products and services including Varespladib. Ophirex operates in a competitive market with competitors including Beijing Kangchen Pharmaceutical, Vins Bio Products, Mediclone Biotech, Mithros Bioscience and VenoMab, among others.
- Headquarter Corte Madera, United States
- Founders Matthew Lewin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ophirex, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.48 M (USD)
in 2 rounds
-
Latest Funding Round
$1.78 M (USD), Grant
Sep 15, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ophirex
Ophirex offers a comprehensive portfolio of products and services, including Varespladib.
Blocks lethal snake venom components for immediate treatment
People of Ophirex
Unlock access to complete
Unlock access to complete
Funding Insights of Ophirex
Ophirex has successfully raised a total of $16.48M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.78 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ophirex
Ophirex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Ophirex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ophirex
Investment portfolio details for Ophirex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ophirex
Detailed financials for Ophirex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ophirex Comparisons
Peer comparison for Ophirex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ophirex
Ophirex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beijing Kangchen Pharmaceutical, Vins Bio Products, Mediclone Biotech, Mithros Bioscience and VenoMab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antivenom drugs and pharmaceutical products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Antisera and antitoxins for snake bites and infections are developed.
|
|
| Locked | Locked | Locked |
Diagnostic kits and therapeutic biologics are manufactured and developed.
|
|
| Locked | Locked | Locked |
Develops anti-venom antibodies for medical applications.
|
|
| Locked | Locked | Locked |
Develops recombinant humanized antibodies targeted against snake venom.
|
Detailed competitors of Ophirex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ophirex
Complete news archive for Ophirex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ophirex
Ophirex was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Ophirex is headquartered in Corte Madera, United States. It is registered at Corte Madera, California, United States.
Nancy J Koch is the current CEO of Ophirex.
Ophirex is a funded company, having raised a total of $16.48M across 2 funding rounds to date.
Ophirex was founded in 2015 and is based in Corte Madera, United States. The company operates in the biotechnology sector, focusing on the development of oral therapies to address snake bite envenomations. Its lead candidate, Varespladib, is designed to inhibit sPLA2, a toxic enzyme found in various snake venoms. Research and drug development activities are centered on improving treatment accessibility in affected regions.
Ophirex's top competitors include Beijing Kangchen Pharmaceutical, Vins Bio Products and Mediclone Biotech.
Ophirex offers Varespladib.
Ophirex has 1 investor. Key investors include HHS.